<DOC>
	<DOCNO>NCT00229632</DOCNO>
	<brief_summary>This study determine whether drug call idebenone safe effective reduce level oxidant believe damage nervous system hearts patient Friedreich 's ataxia . Friedreich 's ataxia cause abnormality gene make protein call frataxin , necessary proper function energy-producing part cell call mitrochondria . In Friedreich 's ataxia , mitochondrion become overload iron , high level harmful compound call oxidant form . These oxidant believe damage cell nervous system hearts people Friedreich 's ataxia . Idebenone man-made drug similar naturally occur compound know Coenzyme Q10 . This study test whether idebenone alleviate symptom Friedreich 's ataxia slow halt progression disease . Patients genetically confirm Friedreich 's ataxia 9 18 year age , weigh 65 175 pound walk 25 foot without assistive device may eligible study . Candidates screen blood test review medical record . Participants undergo follow test procedure : - Medical interview physical examination . Tests include blood urine test , electrocardiogram , EKG ( record electrical activity heart ) , echocardiogram ( ultrasound test show pump action heart , thickness heart wall , valve leakage ) , detailed neurological examination , include maneuver copy draw put pegs board . Patients ' parent ask question feel child 's disease affect child 's quality life . - Magnetic resonance imaging ( MRI ) examine heart muscle blood flow heart . MRI use magnetic field radio wave produce image body tissue organ . The patient lie table move doughnut-shaped MRI scanner , wear earplug muffle loud knock thump sound occur scan process . A catheter ( plastic tube ) place vein child 's arm chemical call gadolinium inject MRI study . Gadolinium brighten area heart , improve ability see heart blood flow . - Physical medicine rehabilitation evaluation test child 's physical functioning . These test include gait evaluation , measurement ability exert maintain constant force , assessment visual-motor control fine motor control , aerobic exercise endurance testing , measurement ability child 's heart lungs increase effectiveness exercise . - Idebenone/placebo treatment . Patients give 6-month supply either idebenone pill placebo ( pill look like study drug active ingredient ) take three time day . Patients see primary care physician 1 3 month study medication brief physical examination . In addition , blood urine test month medication check abnormality . - 6-month examination . After 6 month study drug , patient return NIH repeat test list determine effect idebenone treatment .</brief_summary>
	<brief_title>Idebenone Treat Friedreich 's Ataxia</brief_title>
	<detailed_description>Background : Friedreich 's ataxia ( FA ) progressive , autosomal recessive , multisystem degenerative disease currently effective treatment . Recent study suggest lipid-soluble antioxidant lead modest reversal cardiomyopathy patient FA . It possible antioxidant may also prevent progression neurodegeneration . Objective : This 6 month phase 2 double-blind , placebo-controlled trial ass safety efficacy idebenone administer adolescent child FA . Study Population : We aim enroll 48 subject compose child ( age 9-11 ) adolescent ( age 12-17 ) FA divide evenly among 4 treatment arm ( placebo , low , intermediate , high dose idebenone ) . Design : Our primary objective examine change level oxidative stress measure oxidative marker 8-hydroxy-2-deoxyguanosine baseline 6 month treatment placebo vary dos idebenone . Following informed consent assent , patient undergo initial medical history physical follow specific neurological , functional , cardiac test two-day outpatient visit . Patients provide blood urine sample safety laboratory biochemical analysis . Each patient randomize one 4 treatment arm provide 6 month supply study drug placebo administer three time day . Patients follow-up laboratory monitoring 1 3 month end study . Additionally , patient also EKG , vital sign , include orthostatics , physical examination perform 1 3 month primary care physician . Patients return 6 month follow-up exam , test , laboratory monitor two-day outpatient visit . Outcome Parameters : The primary endpoint phase 2 trial change level oxidative stress marker 8-hydroxy-2-deoxyguanosine . Secondary endpoint include type frequency adverse event , , compliance dose regimen , measurement follow : International Cooperative Ataxia Rating Scale ( ICARS ) , Friedreich 's ataxia Rating Scale ( FARS ) , force control , gait analysis , quantitative sensation testing , fine motor control , health relate quality life score ( SF-10 ) , functional capacity , aerobic capacity , leave ventricular wall mass , noninvasive measure systolic diastolic ventricular function , metabolic marker , marker mitochondrial DNA damage , gene expression profile . Future Directions : We hope result phase 2 study assist u develop multi-center , double-blinded , placebo-controlled phase III trial .</detailed_description>
	<mesh_term>Ataxia</mesh_term>
	<mesh_term>Cerebellar Ataxia</mesh_term>
	<mesh_term>Friedreich Ataxia</mesh_term>
	<mesh_term>Idebenone</mesh_term>
	<mesh_term>Ubiquinone</mesh_term>
	<criteria>INCLUSION CRITERIA : Diagnosis FA confirm FRDA mutation . Age nine eighteen year . Weight 30 80 kilogram . Ambulatory ( assistance device permit ) . Willing participate aspect trial design followup . All subject agree commit use 2 reliable method birth control duration study sexually active . Neurologically symptomatic . No exposure idebenone , coenzyme Q10 , dietary supplement period least one month enrollment study . EXCLUSION CRITERIA : History hypersensitivity reaction idebenone coenzyme Q10 . Pregnant lactate woman . All woman childbearing potential must negative serum pregnancy prior medication phase study . If minor positive pregnancy test , inform inform parent unless ask minor . Platelet count , white blood cell count hemoglobin lower limit normal . Alkaline phosphatase , SGOT , SGPT great 1.5 time upper limit normal . Bilirubin great 1.5 g/dl . Creatinine great 1.5 time upper limit normal base upon pediatric reference range provide test laboratory . Clinically significant medical disease , judgment investigator , would expose patient undue risk harm prevent patient complete study .</criteria>
	<gender>All</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 28, 2016</verification_date>
	<keyword>Friedreich 's Ataxia</keyword>
	<keyword>Idebenone</keyword>
	<keyword>Ataxia</keyword>
	<keyword>Drug Trial</keyword>
	<keyword>Randomized Trial</keyword>
	<keyword>Friedreich Ataxia</keyword>
	<keyword>FA</keyword>
</DOC>